Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686

BACKGROUND: ACRIN 6686/RTOG 0825 was a phase III trial of conventional chemoradiation plus adjuvant temozolomide with bevacizumab or without (placebo) in newly diagnosed glioblastoma. This study investigated whether changes in contrast-enhancing and fluid attenuated inversion recovery (FLAIR)–hyperi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Boxerman, Jerrold L, Zhang, Zheng, Safriel, Yair, Rogg, Jeffrey M, Wolf, Ronald L, Mohan, Suyash, Marques, Helga, Sorensen, A Gregory, Gilbert, Mark R, Barboriak, Daniel P
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2018
Onderwerpen:
Neuroimaging
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6120359/
https://ncbi.nlm.nih.gov/pubmed/29590461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy049
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items